Literature DB >> 1941820

Infection and disease activity in systemic lupus erythematosus: a review of hospitalized patients.

K N Duffy1, C M Duffy, D D Gladman.   

Abstract

Infection is a major cause of morbidity and mortality in systemic lupus erythematosus (SLE). A review of all SLE admissions to our hospital during a 5-year period was conducted to determine the rate and nature of infection, and its association with overall disease activity, measured by the SLE Disease Activity Index (SLEDAI). Eighty-one patients (79 women, 2 men) were admitted for a total of 2,738 days (176 admissions). There were 53 proven infections, giving an infection rate of 1.94/100 hospital days. Twenty-three (43.4%) of these were major infections (requiring IV antibiotics). Two of 3 deaths were due to septicemia. By logistic regression analysis, infection was significantly associated with disease activity (p = 0.005), but not with disease duration or prednisone dosage. Our data confirm that infection is common in hospitalized patients with SLE, is associated with overall disease activity independent of prednisone dose, and causes significant mortality. These facts should be borne in mind when hospitalization is considered for patients with SLE.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1941820

Source DB:  PubMed          Journal:  J Rheumatol        ISSN: 0315-162X            Impact factor:   4.666


  37 in total

Review 1.  Drug-induced lymphopenia: focus on CD4+ and CD8+ cells.

Authors:  P Gergely
Journal:  Drug Saf       Date:  1999-08       Impact factor: 5.606

Review 2.  Infection-related morbidity and mortality in patients with connective tissue diseases: a systematic review.

Authors:  Matthew E Falagas; Katerina G Manta; Gregoria I Betsi; Georgios Pappas
Journal:  Clin Rheumatol       Date:  2006-12-21       Impact factor: 2.980

3.  Serious Infection Rates Among Children With Systemic Lupus Erythematosus Enrolled in Medicaid.

Authors:  Linda T Hiraki; Candace H Feldman; Francisco M Marty; Wolfgang C Winkelmayer; Hongshu Guan; Karen H Costenbader
Journal:  Arthritis Care Res (Hoboken)       Date:  2017-09-21       Impact factor: 4.794

4.  Does erythrocyte sedimentation rate reflect and discriminate flare from infection in systemic lupus erythematosus? Correlation with clinical and laboratory parameters of disease activity.

Authors:  Valentin Sebastian Schäfer; Katharina Weiß; Andreas Krause; Wolfgang Andreas Schmidt
Journal:  Clin Rheumatol       Date:  2018-04-14       Impact factor: 2.980

5.  All-cause hospitalizations in systemic lupus erythematosus from a single medical center in Israel.

Authors:  Ofer Levy; Andrey Markov; Yulia Drob; Ilia Maslakov; Moshe Tishler; Mirit Amit-Vazina
Journal:  Rheumatol Int       Date:  2018-08-27       Impact factor: 2.631

6.  Presence of antibodies to SSB/La is associated with decreased phagocytic efficiency of neutrophils in patients with systemic lupus erythematosus.

Authors:  Debasis Biswas; Amrita Mathias; Rajeshwar Dayal; Amita Aggarwal; Ramnath Misra; Sita Naik
Journal:  Clin Rheumatol       Date:  2007-11-06       Impact factor: 2.980

7.  Fatal infection in children with lupus nephritis treated with intravenous cyclophosphamide.

Authors:  Kamolwish Laoprasopwattana; Pornsak Dissaneewate; Prayong Vachvanichsanong
Journal:  Pediatr Nephrol       Date:  2009-03-12       Impact factor: 3.714

8.  Salmonella septic arthritis in systemic lupus erythematosus and other systemic diseases.

Authors:  J Y Chen; S F Luo; Y J Wu; C M Wang; H H Ho
Journal:  Clin Rheumatol       Date:  1998       Impact factor: 2.980

9.  Clinical and genetic risk factors for pneumonia in systemic lupus erythematosus.

Authors:  Brent W Kinder; Michelle M Freemer; Talmadge E King; Raymond F Lum; Joanne Nititham; Kim Taylor; Jeffrey C Edberg; S Louis Bridges; Lindsey A Criswell
Journal:  Arthritis Rheum       Date:  2007-08

10.  Predictors of major infections in systemic lupus erythematosus.

Authors:  Guillermo Ruiz-Irastorza; Nerea Olivares; Ioana Ruiz-Arruza; Agustin Martinez-Berriotxoa; Maria-Victoria Egurbide; Ciriaco Aguirre
Journal:  Arthritis Res Ther       Date:  2009-07-15       Impact factor: 5.156

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.